# New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
Canonical URL: https://biopharmsignal.com/news/BIAF/new-case-study-bioaffinity-technologies-cypathr-lung-diagnostic-supports-physician-s-assessment-prompts-follow-up-imaging-and-defers-unnecessary-biopsy
Ticker: BIAF
Company: bioAffinity Technologies, Inc.
Source: bioAffinity Technologies, Inc.
Published: 2026-04-14 12:00 EST
Original Source URL: https://ir.bioaffinitytech.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-27 12:08 EST — [bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-publishes-new-clinical-framework-addressing-growing-mar-0496e8ef) — Source: bioAffinity Technologies, Inc.
- 2026-07-22 12:08 EST — [bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-and-pictor-inc-partner-to-develop-and-commercialize-bio-7ee819d4) — Source: bioAffinity Technologies, Inc.
- 2026-07-07 12:46 EST — [bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-quarterly-cypath-lung-sales-double-to-new-record-as-com-fee483fe) — Source: bioAffinity Technologies, Inc.
- 2026-06-22 12:00 EST — [bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-reports-positive-preclinical-findings-showing-proprieta-c62b401e) — Source: bioAffinity Technologies, Inc.
- 2026-06-18 17:16 EST — [bioAffinity Technologies Announces Closing of $3.2 Million Offering](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-announces-closing-of-3-2-million-offering-d0a98ce9) — Source: bioAffinity Technologies, Inc.
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)